Skip to main content

EXAS

Stock

EXAS

Stock
Health Care
Diagnostics & Research

Performance overview

EXAS Price
Price Chart

Forward-looking statistics

Beta
1.19
Risk
53.74%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees6K
Market cap$7.9B

Fundamentals

Enterprise value$11.8B
Revenue$2.8B
Revenue per employee
Profit margin-36.06%
Debt to equity105.93

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.53
Dividend per share
Revenue per share$15.26
Avg trading volume (30 day)$162M
Avg trading volume (10 day)$170M
Put-call ratio

Macro factor sensitivity

Growth+0.8
Credit+4.0
Liquidity+0.5
Inflation-2.4
Commodities+1.0
Interest Rates-4.3

Valuation

Dividend yield0.00%
PEG Ratio-156.94
Price to sales3.56
P/E Ratio-156.94
Enterprise Value to Revenue4.16
Price to book4.20

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

QGEN or EXAS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research (July 10, 2025)
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.

Benzinga (May 2, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free